Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.
glenmark pharmaceuticals ltd
B D S Marg
Chakala, Off Western Express Highway
Phone: 91 22 4018 9999
Fax: 91 22 4018 9990www.glenmarkpharma.com
|Cadila Healthcare Ltd||1,839 INR||+1.25|
|Impax Laboratories Inc||$46.31 USD||-0.34|
|Jubilant Life Sciences Ltd||171.10 INR||+2.25|
|Lannett Co Inc||$57.98 USD||-0.67|
|Taro Pharmaceutical Industries Ltd||$142.46 USD||+0.16|
|View Industry Companies|
Sponsored Financial Commentaries
To contact GLENMARK PHARMACEUTICALS LTD, please visit www.glenmarkpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.